Position in NVAX
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$75
+$10 QoQ
Shares Held
8
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#257
of 263 holders
Holding Since
Jun 2022
13 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SOA Wealth Advisors, LLC. holds $779,280 across 13 Biotechnology names. NVAX ranks #11 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
9,981 | $559,634 | |
| 2 | TECH |
BIO-TECHNE Corp
|
1,468 | $103,714 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
78 | $38,744 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
800 | $31,208 | |
| 5 | ELDN |
Eledon Pharmaceuticals, Inc.
|
4,566 | $17,990 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
36 | $10,837 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
155 | $8,453 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
98 | $7,299 |
All Filings in NVAX
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $75 | 8 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $65 | 8 | Shares | Sole | 2026-05-20 | |
| 2025-12-31 | $53 | 8 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $69 | 8 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $50 | 8 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $51 | 8 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $64 | 8 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $101 | 8 | Shares | Sole | 2024-11-20 | |
| 2024-06-30 | $101 | 8 | Shares | Sole | 2024-07-17 | |
| 2024-03-31 | $38 | 8 | Shares | Sole | 2024-04-10 | |
| 2023-12-31 | $38 | 8 | Shares | Sole | 2024-02-13 | |
| 2022-09-30 | $400 | 22 | Shares | Sole | 2022-10-07 | |
| 2022-06-30 | $1,131 | 22 | Shares | Sole | 2022-07-13 | |
| No filing history on record for this holder in this stock. | ||||||